Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 safety study of AX-5006 in participants with and without Parkinson's disease
NL-OMON60302Phase 1Recruiting
- Sponsor
- Vertero Therapeutics
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of AX-5006 in Parkinson's disease (PD), sponsored by Vertero Therapeutics. Started Oct 2025; status: recruiting.
02
Drugs
AX-5006
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON60302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60302.